NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for lung cancer patients whose tumors resist standard therapy
Disease control OngoingThis phase 3 study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutant non-squamous non-small cell) whose cancer has worsened after initial targeted therapy. About 420 adults aged 18-7…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New drug cocktail shows promise for tough lung cancer
Disease control OngoingThis study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if this mix can shrink tumors or slow the disease. The study includes 29 ad…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 26, 2026 05:47 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis study tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and computer modeling to target their unique tumor. About 90 participants will receive the vaccine plus standard ch…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New hope for lung cancer patients whose current meds stop working?
Disease control OngoingThis study tests a new drug called AK112 combined with standard chemotherapy in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has a mutation in the EGFR gene and has stopped responding to initial targeted therapy. About 322 participants wi…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 18, 2026 12:10 UTC